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Abstract
Cell therapy with adult stem cells is a new battle 
front for the control of aging. Before being used 
for this purpose, we need to answer several basic 
questions about the biochemistry and physiology 
of these cells. This paper presents some aspects 
and preliminary results obtained in our laboratory 
using stem cells from adipose tissue.
Introduction
Various strategies are used to control the effects 
of aging on the normal functions of an organism. 
Antioxidants, diet, exercise and even activating 
enzymes of phase II detoxification appear to delay 
the decay function to a greater or lesser extent. 
However, none of these strategies prevent biological 
aging. Hence, to control the effects of aging it will 
be necessary to emphasize the need to explore the 
mechanisms of tissue repair and regeneration as a 
complementary methodology to other prevention 
strategies. In this sense, Regenerative Medicine 
may represent a fascinating alternative to control 
the aging process. 
One of the aspects of Regenerative Medicine 
is based on the regenerative capacity of adult 
stem cells are in most tissues and contribute to 
this homeostasis and repair. After tissue damage 
several intracellular and intercellular pathways are 
activated in a coordinated attempt to restore the 
tissue integrity. With aging occurs general decline 
in the regeneration potential.  Besides this loss of 
regenerative capacity is produced by alterations of 
the stem cells with aging, it is thought that stem 
cells transplanted into damaged or aged tissues may 
have therapeutic and restorative capacity. In fact, 
stem cells represent a huge promise in the therapy 
of many aging-related degenerative disorders aging 
some diseases such diabetes, heart disease, stroke, 
Parkinson,  etc [1-4] 
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Stem cells
Stem cells have the ability to self-renew 
through symmetric divisions and the potential 
of differentiating into several different cell types 
depending on their degree of multipotentiality 
through asymmetric division [1-3,5-8]. It is now 
known that most of the tissues have a very specific 
population of adult stem cells that allow their 
regular renewal or regeneration [6,8]. Thus, it has 
been described the existence of these SC in tissues 
such as muscle, skin, liver, pancreas, brain [9], 
intestines, fatty tissue [10,11].
In higher animals, stem cells have been classified 
into two groups: embryonic stem cells and organ-
specific stem cells or stem cells from adult tissue. 
The latter are able to originate cells of a particular 
organ in the adult. Our work focuses on adult stem 
cells. The activity of these stem cells varies greatly 
from one organ to another: those of the bone 
marrow that form blood cells are very active and 
are continually dividing, while those which are, for 
example, in the small intestine are more inactive. 
Some adult stem cells are capable of differentiating 
into more than one cell type as mesenchymal stem 
cells. 
Adipose tissue mesenchymal stem cells (ADSC)
Within the adult stem cell group are the 
mesenchymal stem cells (MSC). The MSC belong 
to the mesenchyma, which by a differentiation 
process will lead to the blood vessels, smooth 
muscle, mesothelium, lymphatic system and 
connective tissue itself. These cells can be 
obtained from different organs including fetal 
liver, umbilical cord, and bone marrow [12,13]. 
Another important source is adipose tissue, which 
contains progenitor cells called adipose tissue stem 
cells (ADSC) [2,10,14,15].
Advantage of ADSC
The easy access to the subcutaneous fat by 
liposuction, allows ADSC to be obtained under 
local anesthesia and with minimal discomfort to 
the patient. In addition, its high abundance with 
not ethical problems associated with its use, make 
adipose tissue  an important source of MSC [16-
18]. Another advantage is that the proportion of 
MSC is 500 times higher [19,20] in adipose tissue 
than in the bone marrow, so that a large number 
of cells can be obtained without a large number 
of passes, decreasing the risk of chromosomal 
abnormalities induced senescence in  cultures 
[21]. An additional advantage is its potential to 
differentiate into bone, cartilage, tendons, skeletal 
muscle, fat, endothelial tissue and  macrophages 
when grown under specific conditions of each 
lineage [11,13,22]. Surprisingly, the ADSC not 
only have the potential to differentiate into cells of 
mesodermal origin and organs, but also they have 
the ability to differentiate into neurons, endocrine 
cells of the pancreas, hepatocytes, endothelial cells 
and cardiomyocytes [10].
ADSCs can repair and regenerate the tissues by 
several mechanisms: First, the ADSC transplanted 
into a damaged or diseased tissue can secrete 
cytokines and growth factors that stimulate the 
recovery in a paracrine manner. The ADSC could 
modulate the host stem cell niche by stimulating 
the recruitment of endogenous stem cells to a 
particular site and promote their differentiation 
into the required lineage. Also, ADSC can provide 
antioxidants so that toxic substances released into 
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the local environment are eliminated, thereby 
promoting the recovery of the surviving cells. 
Another mechanism is thought their in vitro 
differentiation into the desired line, prior to their 
autologous transplantation [2]. They can also act as 
immune modulators [23]. 
Today it is possible to isolate and culture adult 
stem cells for therapeutic use. Once transplanted, 
these cells can be used to rejuvenate damaged 
tissue by aging or other causes. However, no 
one knows for sure the consequences of the 
stem cells treatments because there are many 
basic questions about the biology of these CM 
that must be answered before its therapeutic use. 
Obviously, these cells have to survive and perform 
their function in unfavourable conditions as the 
damaged tissue microenvironment, where many 
factors needed for stem cells are lacking. Under 
these adverse conditions, the survival of the 
stem cells will depend on his “molecular health” 
and its responsiveness when implanted in the 
tissue. Therefore, stem cells must have a robust 
repair mechanisms and resistance in order to 
participate in tissue regeneration. It is likely that 
this molecular health and stress response depends 
on many biochemical and physiological aspects 
related to donor age, lifestyle, etc. As these cells are 
continuously receiving “on-off” signals to divide, 
it could be that old cells are less sensitive to these 
signals. Consequently, the therapeutic applications 
of stem cells in adult tissue repair requires a better 
understanding of the biology of these cells, of the 
environment of the damaged tissue or both. 
The work we are carrying out in our laboratory 
try to answer several of these basic questions about 
ADSC. 
First of all, we focused on the isolation methods. 
These methods are based on magnetic cell sorting 
(Miltenyi Biotech), where magnetic microparticles 
linked to antibodies recognize surface antigen in 
the stem cells.  The separation is performed on a 
column inserted in an extremely powerful magnet 
to retain the labeled cells. This methodology allows 
us to build a cell bank of patients of different ages 
that meet the criteria of “Mesenchymal and Tissue 
Stem Cell Committee of the International Society 
for Cellular Therapy.”
The first criteria is that cells must be adherent to 
the plastic. The photographs of Figure 1 show that 
the human ADSC are adherent to the culture flask 
without addition of any substrate.
Figure 1. Human ADSC (42 yrs) in culture flask. 10x 
magnification.
A prerequisite for considering the cultured 
ADSC as MSC, is to demonstrate that they have 
the potential to differentiate into at least two 
different cell types [11,13,22,24]. For this, cells 
were cultured in specific differentiating media. 
Figure 2 shows photographs taken before and after 
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differentiation into adipocytes, where it can be 
observed fusiform cells containing lipid vacuoles. 
The red staining of these vacuoles (Fig. 2 and B) 
shows the differentiation into  adipocytes ADSCs. 
Furthermore, the presence of black-purple 
shown by the presence of alkaline phosphatase 
in osteoblasts generated by ADSC differentiation 
(Fig. 2C)
In addition to the ability of adherence to plastic 
and differentiation, the results provided by flow 
cytometry serve to confirm the nature of the cells 
obtained. Figure 3 show the results obtained from 
a cell population of human ADSC. These graphs 
represents side scatter (Side Scatter, SS), which 
gives information about the existence of different 
cell populations. The forward scatter (forward 
scatter, FS), gives an insight on cell size. As can be 
seen, the sample contains a unique cell population, 
reflected in the graph as a single cloud. 
To verify that the obtained cells meet the 
minimum standards required by the committee 
of mesenchymal stem cells and tissues of the 
international cell therapy, cells must have the 
surface markers CD73, CD90 and CD105. On the 
contrary, they should not contain CD14, CD34, 
CD45, CD19, CD79α and human leukocyte 
antigen (HLA)-DR.
Figure 2. Differentiation of human ADSC into adipocytes 
and osteoblasts. A) Picture of human adipocytes obtained 
from ADSC (patient of 37 years) prior to staining, 10X 
magnification. B) Photograph after fixation and staining 
process. C) Photograph of osteoblasts after fixing and stai-
ning 20X magnification. 
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The histograms represent the number of events 
counted on each exposed channel. In our case, 
the channel FL1, FL2 and FL4 are set to excite 
the fluorophores FITC, PE, PerCP, respectively. 
Considering the antibodies used, (CD14-PerCP, 
CD20-PerCP, CD34-PerCP, CD45-PerCP, 
CD105-FITC and CD90-PE), FL1 channel gives 
us information on the number of cells expressing 
CD90 marker (Fig. 3B); FL2 channel gives 
information about the proportion of CD105-
expressing cells (Fig. 5C) and FL4 channel 
indicates the percentage of positive cells is any 
of the following markers: CD14, CD20, CD34 
and CD45 (Fig. 3D). The first histogram (Fig. 
3B) indicates that 94.53% of the sample is positive 
for the CD90 marker. The second histogram 
(Fig. 3C) shows that almost 100% of the sample 
expressed the marker CD105. Only 9.5% of the 
cells have one of the following markers: CD14, 
CD20, CD34, CD45. 
Finally, we have used a method for labeling and 
tracking that allow us to monitor stem cells once 
they are injected in vivo. This method is based in 
transfecting the ADSC with the luciferase gene 
by using lentivirus. After intraperitoneal injection 
of luciferin, cells carrying the luciferase gen can 
be observed by using an in vivo imaging system. 
Figure 4A shows a culture of transfected ADSC in 
a 25 cm 2 flask prior to administration of 3 luciferin 
used as a control of bioluminescence. Figure 4B 
shows the same culture after the administration of 
D-luciferin.
Figure 3. Study of the degree of cellular homogeneity 
and phenotyping of human ADSC. Data were obtained 
from the flow cytometer FC-500 (Beckman-Coulter). The 
results of positive events to the fluorophore are in %.
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Conclusion
In summary, we can say that cell therapy open a 
new battle front in the control and treatment of 
aging related diseases. However, there are many 
basic questions about the biology of these stem cells 
that should be answered to predict the therapeutic 
potential of these cells, some of which are going to 
be known after the completion of the the present 
study because. The main objective of this work is 
to identify the factors affecting the “robustness” of 
the biochemistry and physiology of ADSC. 
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